Alkem Laboratories Limited (ALKEM.BO)
INR 4835.45
(2.88%)
INR 4835.45
(2.88%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 24.19 Billion INR | 23.0% |
| 2022 | 17.22 Billion INR | -16.71% |
| 2021 | 21.9 Billion INR | 5.46% |
| 2020 | 21.75 Billion INR | 31.04% |
| 2019 | 15.77 Billion INR | 32.12% |
| 2018 | 11.95 Billion INR | 4.93% |
| 2017 | 11.19 Billion INR | 3.37% |
| 2016 | 11.06 Billion INR | 9.03% |
| 2015 | 10.92 Billion INR | 69.36% |
| 2014 | 6 Billion INR | 2.92% |
| 2013 | 5.89 Billion INR | -6.59% |
| 2012 | 6.23 Billion INR | 18.97% |
| 2011 | 5.34 Billion INR | 37.35% |
| 2010 | 4.18 Billion INR | 41.76% |
| 2009 | 2.82 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 6.08 Billion INR | 52.62% |
| 2023 Q1 | 4.55 Billion INR | 7.85% |
| 2023 FY | - INR | 23.0% |
| 2023 Q3 | 8.01 Billion INR | -1.07% |
| 2023 Q4 | 4.01 Billion INR | -49.83% |
| 2023 Q2 | 8.09 Billion INR | 77.99% |
| 2022 Q2 | 5.04 Billion INR | 98.15% |
| 2022 Q4 | 4.21 Billion INR | -34.52% |
| 2022 FY | - INR | -16.71% |
| 2022 Q1 | 2.54 Billion INR | -23.74% |
| 2022 Q3 | 6.44 Billion INR | 27.71% |
| 2021 FY | - INR | 5.46% |
| 2021 Q4 | 3.33 Billion INR | -39.5% |
| 2021 Q3 | 5.51 Billion INR | -17.16% |
| 2021 Q1 | 6.39 Billion INR | 166.38% |
| 2021 Q2 | 6.66 Billion INR | 4.2% |
| 2020 Q3 | 6.25 Billion INR | -1.65% |
| 2020 Q2 | 6.36 Billion INR | 10.29% |
| 2020 Q1 | 5.76 Billion INR | 70.19% |
| 2020 FY | - INR | 31.04% |
| 2020 Q4 | 2.4 Billion INR | -61.62% |
| 2019 FY | - INR | 32.12% |
| 2019 Q3 | 4.81 Billion INR | -0.6% |
| 2019 Q2 | 4.84 Billion INR | 71.65% |
| 2019 Q1 | 2.81 Billion INR | 8.2% |
| 2019 Q4 | 3.38 Billion INR | -29.57% |
| 2018 FY | - INR | 4.93% |
| 2018 Q4 | 2.6 Billion INR | -18.85% |
| 2018 Q3 | 3.21 Billion INR | -17.28% |
| 2018 Q2 | 3.88 Billion INR | 68.43% |
| 2018 Q1 | 2.3 Billion INR | 75.11% |
| 2017 Q4 | 1.31 Billion INR | -65.76% |
| 2017 FY | - INR | 3.37% |
| 2017 Q1 | 1.23 Billion INR | -28.76% |
| 2017 Q2 | 4.84 Billion INR | 291.14% |
| 2017 Q3 | 3.84 Billion INR | -20.66% |
| 2016 FY | - INR | 9.03% |
| 2016 Q3 | 2.93 Billion INR | -14.77% |
| 2016 Q4 | 1.73 Billion INR | -40.76% |
| 2016 Q1 | 2.99 Billion INR | 15.31% |
| 2016 Q2 | 3.44 Billion INR | 15.12% |
| 2015 Q1 | 2.53 Billion INR | 39.73% |
| 2015 Q2 | 3.25 Billion INR | 28.42% |
| 2015 FY | - INR | 69.36% |
| 2015 Q4 | 2.59 Billion INR | -3.34% |
| 2015 Q3 | 2.68 Billion INR | -17.63% |
| 2014 Q1 | 1.02 Billion INR | 0.0% |
| 2014 FY | - INR | 2.92% |
| 2014 Q4 | 1.81 Billion INR | -13.55% |
| 2014 Q2 | 1.02 Billion INR | 0.0% |
| 2014 Q3 | 2.1 Billion INR | 104.43% |
| 2013 FY | - INR | -6.59% |
| 2012 FY | - INR | 18.97% |
| 2011 FY | - INR | 37.35% |
| 2010 FY | - INR | 41.76% |
| 2009 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | -151.595% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 60.842% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | -252.55% |
| Granules India Limited | 8.6 Billion INR | -181.213% |
| Indoco Remedies Limited | 2.64 Billion INR | -814.039% |
| Achyut Healthcare Limited | 524 Thousand INR | -4617285.496% |
| Ajanta Pharma Limited | 12.56 Billion INR | -92.553% |
| Alpa Laboratories Limited | 86.12 Million INR | -27992.352% |
| Brooks Laboratories Limited | 41.72 Million INR | -57882.889% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -926.608% |
| Bajaj HealthCare Limited | 444.51 Million INR | -5343.021% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -1535.876% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 72.591% |
| Eris Lifesciences Limited | 6.98 Billion INR | -246.315% |
| FDC Limited | 4.4 Billion INR | -449.678% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | -113.291% |
| Gufic Biosciences Limited | 1.48 Billion INR | -1534.267% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | -252.614% |
| Ipca Laboratories Limited | 13.29 Billion INR | -81.925% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -7380.09% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 29346.921% |
| Lasa Supergenerics Limited | -65.08 Million INR | 37277.474% |
| Laurus Labs Limited | 8 Billion INR | -202.212% |
| Lupin Limited | 36.96 Billion INR | 34.554% |
| Mankind Pharma Limited | 28.09 Billion INR | 13.88% |
| Medicamen Biotech Limited | 245.66 Million INR | -9749.019% |
| Medico Remedies Limited | 150.37 Million INR | -15989.521% |
| Megasoft Limited | 284.73 Million INR | -8397.529% |
| NATCO Pharma Limited | 18.79 Billion INR | -28.732% |
| Piramal Pharma Limited | 13.05 Billion INR | -85.326% |
| RPG Life Sciences Limited | 1.28 Billion INR | -1788.03% |
| Sigachi Industries Limited | 883.39 Million INR | -2638.867% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 82.513% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -417.301% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -5523.158% |
| Unichem Laboratories Limited | 742.35 Million INR | -3159.231% |
| Wanbury Limited | 985.49 Million INR | -2355.134% |
| Windlas Biotech Limited | 781.72 Million INR | -2995.111% |
| ZIM Laboratories Limited | 462.09 Million INR | -5135.935% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 56.965% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 748.442% |
| Divi's Laboratories Limited | 25.43 Billion INR | 4.856% |
| Hester Biosciences Limited | 539.47 Million INR | -4384.976% |
| Procter & Gamble Health Limited | 3.01 Billion INR | -702.651% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -3444.872% |
| Bal Pharma Limited | 345.59 Million INR | -6901.059% |
| Strides Pharma Science Limited | 3.76 Billion INR | -542.687% |
| Venus Remedies Limited | 711.8 Million INR | -3299.138% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -518.892% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -1447.209% |
| Shilpa Medicare Limited | 2.58 Billion INR | -834.902% |
| Aarti Drugs Limited | 3.24 Billion INR | -644.779% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -828.225% |
| Suven Life Sciences Limited | -992.78 Million INR | 2537.106% |
| Ind-Swift Limited | 1.06 Billion INR | -2171.7% |
| Valiant Laboratories Limited | 12.73 Million INR | -189829.351% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | -159.192% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 957.405% |
| Themis Medicare Limited | 562.6 Million INR | -4200.533% |
| Hikal Limited | 2.69 Billion INR | -798.701% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 30.89% |
| Sequent Scientific Limited | 549.8 Million INR | -4300.709% |
| Novartis India Limited | 1.26 Billion INR | -1806.177% |
| Wockhardt Limited | 1.08 Billion INR | -2140.287% |
| Jubilant Pharmova Limited | 8 Billion INR | -202.212% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -185132.736% |
| Neuland Laboratories Limited | 4.74 Billion INR | -409.565% |
| Morepen Laboratories Limited | 1.72 Billion INR | -1301.839% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -8317.883% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -13730.039% |